Therapy-Related Acute Promyelocytic Leukemia

Beaumont, Marie; Sanz, Miguel Á.; Carli, Paule‐Marie; Maloisel, Frédéric; Thomas, Xavier; Detourmignies, Laurence; Guerci, Agnès; Gratecos, N; Rayón, Consuelo; Miguel, Jesús F. San; Odriozola, J; Cahn, Jean‐Yves; Huguet, Françoise; Vekhof, A.; Stamatoulas, Aspasia; Dombret, Hervé; Capote, Francisco; Esteve, Jordi; Stoppa, Anne Marie; Fenaux, Pierre

doi:10.1200/jco.2003.09.072

Cited by 200 publications

(184 citation statements)

References 53 publications

Supporting

Mentioning

166

Contrasting

Unclassified

Order By: Relevance

“…The outcome of therapyrelated acute promyelocytic leukemia (APL) has been recently reported to be similar to de novo APL. 35 The other patient with AML M4eo inv(16) achieved CR, but Secondary AML after mitoxantrone-based HD chemotherapy for breast cancer N Kröger et al died during treatment of infectious complications. Only the death of the third patient was due to relapse of AML.…”

Section: Discussionmentioning

confidence: 99%

Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients

Kröger

Damon

Zander

et al. 2003

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy. The median age of the patients was 57 years (range 22-67). In all, 268 patients received peripheral blood stem cells, and 47 patients received autologous bone marrow. After a median followup of 57 months (range 10-125), three cases of secondary AML (sAML) were observed, resulting in a cumulative incidence of 0.94%. One case of sAML developed 18 months after HDCT (FAB M3) The karyotype was translocation 15;17 and, after induction therapy, the patient underwent autologous stem cell transplantation, and is in complete remission (CR) of both breast cancer and AML. The second patient developed AML (FAB M4eo with inversion 16) 5 months after HDCT. This patient achieved CR after induction therapy, but died of infectious complication. A third patient developed AML (FAB M4) 6 months after HDCT. She achieved CR after induction therapy, but relapsed and expired 28 months after diagnosis of AML. sAML after mitoxantrone-based HDCT is a possible, but rare complication in breast cancer patients. Bone Marrow Transplantation (2003) 32, 1153-1157. doi:10.1038/sj.bmt.1704291 Keywords: high-dose chemotherapy; adjuvant therapy; breast cancer; mitoxantrone; secondary AML Secondary myelodysplasia (MDS) or acute myeloid leukemia (AML) in breast cancer patients is a rare but wellknown long-term complication of prior chemotherapy or radiation therapy as adjuvant therapy. 1-3 Specific risk factors are the combinations of chemotherapy and radiation therapy, the cumulative dose of alkylating agents and the duration of therapy. 2 Two different types of treatmentrelated leukemia can be distinguished. The first type results from prior therapy with alkylating agents or radiation therapy, and occurs after a latency period of 5-7 years. This type of AML is often preceded by a preleukemic period of MDS. Nearly 90% of the patients with alkylating agentrelated MDS or AML show clonal chromosome aberrations including monosomy or deletions on chromosomes 5 and/or 7 or complex aberrations involving chromosomes 3, 12, 17, and 21. 4 The second type of therapy-related leukemia is induced by topoisomerase II-targeted drugs like etoposide, anthracyclines or, recently, anthracenediones. [5][6][7] This type of AML usually occurs after a median of 2 years and is not preceded by a myelodysplastic syndrome. According to the French-American-British (FAB) classification, more frequently, M4 or M5 subtype is observed and cytogenetic analysis showed a high frequency of rearrangements of the chromosome band as 11q23, translocation (t)(8;21), t(15;17), inversion 16 (inv(16)) or t(8;16), as in de novo AML. 5,8 Recently, several studies indicated that adjuvant chemotherapy consisting of the anthracenedione mitoxantrone, a topoisomerase II-targeted drug, may induce sec...

show abstract

Section: Discussionmentioning

confidence: 99%

Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients

Kröger

Damon

Zander

et al. 2003

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…The occurrence of acute promyelocytic leukemia (APL) in MS patients treated with mitoxantrone has been well documented (Table 1). [2][3][4][5][6] We report two new cases of APL in MS patients following treatment with mitoxantrone.…”

mentioning

confidence: 93%

Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis

et al. 2006

View full text Add to dashboard Cite

“…135 Notably, in patients with CBF AML who were treated with postremission therapy with high-dose cytarabine, the presence of c-KIT mutations resulted in poorer outcomes. 33 In an analysis of patients with CBF AML treated on CALGB trials (n = 110), c-KIT mutations among patients with inv (16) were associated with a higher cumulative incidence of relapse at 5 years (56% vs. 29%; P = .05) and decreased 5-year OS rate (48% vs. 68%) compared with wild-type c-KIT; in multivariate analysis, the presence of c-KIT mutations remained a significant predictor of decreased OS in the subgroup with inv (16). In patients with t(8;21), c-KIT mutations were also associated with a higher incidence of relapse at 5 years (70% vs. 36%: P = .017), but no differences were observed in 5-year OS (42% vs. 48%).…”

Section: Postremission or Consolidation Therapymentioning

confidence: 96%

“…40 Similarly, the benefit in OS outcomes seen with CEBPA mutations seems to be lost in the presence of concurrent FLT3-ITD. 54 As previously mentioned, (16). 27,33,35,72 In a recent analysis from the German-Austrian AML Study Group, the frequency and prognostic impact of secondary genetic lesions were evaluated in patients with CBF AML who were treated in prospective trials (n=176).…”

Section: Molecular Markers and Risk Stratificationmentioning

confidence: 99%

See 1 more Smart Citation

Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR

Mizutani

Hara

Fujita

et al. 2016

Bone Marrow Transplant

View full text Add to dashboard Cite

Therapy-Related Acute Promyelocytic Leukemia

Cited by 200 publications

References 53 publications

Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients

Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients

Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis

Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR

Contact Info

Product

Resources

About